ideasIdea
A guideline fast track for repurposed drugs with phase 3 evidence but no manufacturer
Guidelines usually wait for a drug to be licensed for a use before recommending it. For old drugs no one will license, guidelines should act directly on trial evidence.
Guideline bodies (NCCN, ESMO, NICE) do recommend off-label uses but often slowly and inconsistently for interventions without a sponsor to submit evidence. The proposal is a standing fast-track procedure in major guideline organisations, triggered automatically by publication of a registration-quality randomised trial of an off-patent drug, with a decision within six months, an explicit statement of the recommendation's reimbursement implications, and a mechanism for payers to adopt it in the absence of a label.
Hypothesis
Fast-tracked repurposed interventions reach guideline recommendation within six months of publication (versus a historical median of two or more years) and prescribing uptake within two years exceeds 50% of eligible patients.
Rationale
For off-patent drugs, guidelines rather than labels are the practical gateway to routine use and reimbursement; making the pathway explicit removes an arbitrary disadvantage relative to sponsored drugs.
What would test it
Audit the time from publication to guideline inclusion for the last ten positive repurposing trials; implement the fast track in one guideline body and measure the next five.
Maturity
speculative
Who has to act
clinic
Cost to try
Small (under $1M)
Years to first evidence
2
Bottlenecks it attacks
- No incentive to repurpose cheap drugs · Old, cheap drugs with anti-cancer signals never get the trials they need because no one profits from the result.
- Knowledge reaches practice too slowly · Knowledge diffusion is slow: it takes years for a proven result to change what most patients receive, and no one can keep up with the literature.